Nutex Health (NUTX) investor relations material

Executive summary

• Net income attributable to shareholders rose to $65.8M (EPS $9.38) in Q2 2026, reversing a prior-year loss, with six-month net income at $112.6M (EPS $15.87), up from $3.5M, driven by lower stock-based compensation and reduced arbitration costs.

• Patient visits increased 9.6% year-over-year in Q2, with same-hospital visits up 6.3%.

• Achieved strong operational and financial results in Q2 2026, with improved profitability despite a year-over-year revenue decline due to prior period IDR catch-up effects.

• Continued expansion of hospital network and service lines, with three new facilities expected to open in late 2026 and additional projects in the pipeline for 2027 and beyond.

• Regulatory and legal wins reinforced the integrity of the IDR process, supporting fair reimbursement and reducing arbitration-related costs.

Financial highlights

• Q2 2026 revenue decreased 13.6% year-over-year to $210.8M; six-month revenue down 6.3% to $427.2M.

• Net income for Q2 2026 was $65.8M (EPS $9.38), up from a $17.7M loss in Q2 2025; six-month net income was $112.6M.

• Adjusted EBITDA for Q2 rose to $90M (Q2 2025: $71.6M); six-month adjusted EBITDA up to $147.5M.

• Gross profit margin improved to 67% in Q2 2026 from 51.2% in Q2 2025.

• Cash on hand increased to $205.2M at June 30, 2026, up from $185.6M at year-end 2025.

Outlook and guidance

• Management expects a 25–30% reduction in normalized contract services expenses due to arbitration process changes and CMS fee reductions.

• Expect revenue per visit to remain stable in the $4,000–$4,200 range, with potential upside from increased inpatient volumes and new service lines.

• Hospital opening cadence remains at 3–5 per year, with flexibility to adjust based on market opportunities.

• Arbitration and contract services costs projected to decrease to the high teens–low 20s percent of arbitration-related revenue due to regulatory and vendor contract changes.

• Ongoing regulatory and legal uncertainty around the No Surprises Act and IDR process may continue to impact revenue recognition and financial volatility.